Cell viability effects of triamcinolone acetonide and preservative vehicle formulations

British Journal of Ophthalmology

Volumn 90, Issue 2, 2006, Pages 233-236

  Shaikh, Saad ^a,b   Ho, S ^b   Engelmann, L A ^b   Klemann, S W ^b  

^a Rollins College and Central Florida Retina Consultants ^*  (United States)

^b ROLLINS COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DRUG VEHICLE; PRESERVATIVE; TAMOXIFEN; TETRAZOLIUM; TRIAMCINOLONE ACETONIDE;

ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; VITREOUS DISEASE;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE; CELL SURVIVAL; CULTURE MEDIA; HUMANS; MICROSCOPY, PHASE-CONTRAST; PIGMENT EPITHELIUM OF EYE; PRESERVATIVES, PHARMACEUTICAL; RETINA; TAMOXIFEN; TRIAMCINOLONE ACETONIDE; VEHICLES;

EID: 31544449973     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.076190     Document Type: Article

References (17)

1. Jonas JB, Sofker A, Hayler J, et al. Intravitreal crystalline triamcinolone acetonide as an additional tool in pars plana vitrectomy for complicated proliferative vitreoretinopathy? Acta Ophthalmol Scand 2003;81:663-5.
2. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-50.
3. Jonas JB, Akkoyun I, Kreissig I, et al. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br J Ophthalmol, 2005 Mar, 89:321-6.
4. Jonas JB, Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005;19:65-71.
5. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-91.
6. Yeung CK, Chan KP, Chiang SW, et al. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 2003;44:5293-300.
7. Hida T, Chandler D, Arena JE, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190-5.
8. Hetherington NJ, Dooley MJ. Potential for patient harm from intrathecal administration of preserved solutions. Med J Aust 2000;173:141-3.
9. McCuen BW II, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-8.
10. Perry HT, Cohn BT, Nauheim JS. Accidental intraocular injection with Dermojet syringe. Arch Dermatol 1977;113:1131 (letter).
11. Modarres M, Parvaresh MM, Peyman GA. Accidental sub-retinal injection of triamcinolone acetonide. Ophthalmic Surg lasers 1998;29:935-8.
12. Kivilcim M, Peyman GA, El-Dessouky ES, et al. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000;31:474-8.
13. Dunn KC, Aotaki-Keen AE, Putkey FR, et al. ARPE19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 1996;62:155-69.
14. Mannerstrom M, Zorn-Kruppa M, Diehl H, et al. Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells. Toxicol In Vitro 2002;16:193-200.
15. Mannerstrom M, Maenpaa H, Toimela T, et al. The phagocytosis of rod outer segments is inhibited by selected drugs in retinal pigment epithelial cell cultures. Pharmacol Toxicol 2001;88:27-33.
16. Wu W, Kao Y, et al. A comparative study of effects of antiproliferative drugs on human retinal pigment epithelial cells in vitro. J Ocular Pharmacol Ther 2002;18:251-63.
17. Bakri S, Shah A, et al. Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema. Eye 2004:1-3.